Get started
Work

Abstract PS3-08-06: Elegant: elacestrant versus standard endocrine therapy (ET) in women and men with node-positive, estrogen receptor-positive (ER+), HER2-negative (HER2-), early breast cancer (eBC) with high risk of recurrence in a global, multicenter, randomized, open-label phase 3 study

Year: 2026
Type: conference-abstract
DOI: 10.1158/1557-3265.sabcs25-ps3-08-06
Authors: A. Bardia, V. Kaklamani, J. O’Shaughnessy, P. Schmid, T. Beck, M. De Laurentiis, G. Curigliano, H. S. Rugo, C. H. Barcenas, W. J. Gradishar, M. Ignatiadis, D. A. Cameron, G. Tonini, S. Scartoni, J. Crozier, T. Wasserman, S. Tolaney
Institutions: University of California, Los Angeles, UCLA Health, UCLA Jonsson Comprehensive Cancer Center, The University of Texas at San Antonio Health Science Center, Baylor University Medical Center, Queen Mary University of London, Barts Cancer Institute, Highlands Oncology Group, Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", University of Milan, European Institute of Oncology, City Of Hope National Medical Center, City of Hope, The University of Texas MD Anderson Cancer Center, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Université Libre de Bruxelles, Institut Jules Bordet, Institute of Genetics and Cancer, University of Edinburgh, Menarini Group (Italy), Dana-Farber Cancer Institute
Language: English
Field: Medicine
Open Access status: closed
OpenAlex ID: W7130684387
Cites:
Cited by:
Related to: